Search

Your search keyword '"Xia, Lingfang"' showing total 36 results
Start Over Author "Xia, Lingfang"
36 results on '"Xia, Lingfang"'

3. The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Author

XIA Lingfang, ZHU Jun, WU Xiaohua

Subjects
cervical cancer, ovarian cancer, endometrial cancer, immunotherapy, targeted therapy, antibody-drug conjugate, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Many major research achievements have been made in the past year in the field of gynecologic oncology (cervical cancer, ovarian cancer and endometrial cancer), including surgical treatment, local advanced treatment mode and exploration of new treatments for recurrence and metastasis. Especially the research of emerging treatment methods such as immunotherapy, targeted therapy and antibody-drug conjugate therapy has opened a new era of treatment and brought more hopes for treatment to patients. This paper summarizes the major advances in surgical treatment, radiotherapy, chemotherapy and novel targeted immunotherapy for gynecologic oncology at 2023 Annual Meeting of European Society for Medical Oncology (ESMO), in order to better guide the individualized precision treatment.

Published
2023
Full Text
View/download PDF

4. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

Author

Xia, Lingfang, Wang, Jing, Wang, Chunyan, Zhang, Qingming, Zhu, Jianqing, Rao, Qunxian, Cheng, Huijun, Liu, Zheng, Yin, Yongmei, Ai, Xiaohong, Gulina, Kurban, Zheng, Hong, Luo, Xiaoyong, Chang, Baoping, Li, Li, Liu, Haiyan, Li, Yunxia, Lou, Ge, Zhou, Qi, Zhu, Yanling, Xiao, Zemin, Tong, Jiandong, Wang, Ke, Chen, Jie, Wang, Xia, Song, Lijie, Wei, Zhixia, Ye, Yijing, Zhu, Jiman, and Wu, Xiaohua

Published
2023
Full Text
View/download PDF

15. 673 Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II study

Author

Wu, Xiaohua, primary, Xia, Lingfang, additional, Wang, Jing, additional, Wang, Chunyan, additional, Zhang, Qingming, additional, Zhu, Jianqing, additional, Rao, Qunxian, additional, Cheng, Huijun, additional, Liu, Zheng, additional, Yin, Yongmei, additional, Ai, Xiaohong, additional, Gulina, Kurban, additional, Zheng, Hong, additional, Luo, Xiaoyong, additional, Chang, Baoping, additional, Li, Li, additional, Liu, Haiyan, additional, Li, Yunxia, additional, Lou, Ge, additional, Zhou, Qi, additional, Zhu, Yanling, additional, Xiao, Zemin, additional, Tong, Jiandong, additional, Wang, Ke, additional, Chen, Jie, additional, Wang, Xia, additional, Song, Lijie, additional, Wei, Zhixia, additional, Ye, Yijing, additional, and Zhu, Jiman, additional

Published
2022
Full Text
View/download PDF

16. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

Author

Xia, Lingfang, primary, Peng, Jin, additional, Lou, Ge, additional, Pan, Mei, additional, Zhou, Qi, additional, Hu, Wenjing, additional, Shi, Huirong, additional, Wang, Li, additional, Gao, Yunong, additional, Zhu, Jianqing, additional, Zhang, Yu, additional, Sun, Rong, additional, Zhou, Xianfeng, additional, Wang, Quanren, additional, and Wu, Xiaohua, additional

Published
2022
Full Text
View/download PDF

18. Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses

Author

Wu,Yong, Xia,Lingfang, Guo,Qinhao, Zhu,Jun, Deng,Yu, and Wu,Xiaohua

Subjects
Cancer Management and Research
Abstract

Yong Wu,1,2,* Lingfang Xia,1,2,* Qinhao Guo,1,2,* Jun Zhu,1,2 Yu Deng,2,3 Xiaohua Wu1,2 1Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 3Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaohua WuDepartment of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, People’s Republic of China, Tel/Fax +86 21-64175590Email docwuxh@hotmail.comPurpose: High-grade serous ovarian cancer (HGSOC) is the leading cause of death among gynecological malignancies. This is mainly attributed to its high rates of chemoresistance. To date, few studies have investigated the molecular mechanisms underlying this resistance to treatment in ovarian cancer patients. In this study, we aimed to explore these molecular mechanisms using bioinformatics analysis.Methods: We analyzed microarray data set GSE51373, which included 16 platinum-sensitive HGSOC samples and 12 platinum-resistant control samples. Differentially expressed genes (DEGs) were identified using RStudio. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using DAVID, and a DEG-associated protein–protein interaction (PPI) network was constructed using STRING. Hub genes in the PPI network were identified, and the prognostic value of the top ten hub genes was evaluated. MGP, one of the hub genes, was verified by immunohistochemistry.Results: All samples were confirmed to be of high quality. A total of 109 DEGs were identified, and the top ten enriched GO terms and four KEGG pathways were obtained. Specifically, the PI3K-AKT signaling pathway and the Rap1 signaling pathway were identified as having significant roles in chemoresistance in HGSOC. Furthermore, based on the PPI network, KIT, FOXM1, FGF2, HIST1H4D, ZFPM2, IFIT2, CCNO, MGP, RHOBTB3, and CDC7 were identified as hub genes. Five of these hub genes could predict the prognosis of HGSOC patients. Positive immunostaining signals for MGP were observed in the chemoresistant samples.Conclusion: Taken together, the findings of this study may provide novel insights into HGSOC chemoresistance and identify important therapeutic targets.Keywords: high-grade serous ovarian cancer, chemoresistance, gene expression profiling, bioinformatics analysis

Published
2020

24. Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.

Author

Wu, Xiaohua, primary, Xia, Lingfang, additional, Zhou, Qi, additional, Zhu, Jianqing, additional, Wang, Ke, additional, Chen, Jie, additional, Huang, Yi, additional, Kurb, Gulina, additional, Chang, Baoping, additional, Zhao, Weidong, additional, Wang, Xia, additional, Yang, Yingjie, additional, Lin, Zhongqiu, additional, Luo, Xiaoyong, additional, Lou, Ge, additional, Wang, Chunyan, additional, Wang, Jing, additional, and Meng, Haijin, additional

Published
2020
Full Text
View/download PDF

34. Luteinizing hormone compromises the in vivo anti‑tumor effect of cisplatin on human epithelial ovarian cancer cells.

Author

Huang, Yan, Zhou, Yuqi, Xia, Lingfang, Tang, Jia, WEN, Hao, and Zhang, Meiqin

Subjects
OVARIAN cancer treatment, LUTEINIZING hormone, PLATINUM, CANCER chemotherapy, CISPLATIN, DRUG resistance in cancer cells, THERAPEUTICS
Abstract

Platinum‑based chemotherapy is the most common therapeutic regimen used to treat patients with ovarian cancer. However, the emergence of drug resistance to platinum compromises the clinical success of this treatment. Epithelial ovarian cancer is usually accompanied by an increased level of luteinizing hormone (LH). Therefore, the effect of LH on platinum resistance requires further investigation. In the current study, the effect of cisplatin and/or LH on platinum resistance was examined using the SKOV3ip1 and HeyA8 models. Following therapy, tumors were examined for proliferation (ki67) and apoptosis (cleaved caspase‑3). Cisplatin alone and in combination with LH significantly inhibited tumor growth in SKOV3ip1‑ and HeyA8‑implanted mice. Treatment with LH alone had minimal effect in the models. However, treatment with cisplatin combined with LH was less effective than treatment with cisplatin alone. Additionally, ki67 counts were significantly increased and cleaved caspase‑3 counts were significantly reduced in mice treated with cisplatin combined with LH compared with mice treated with cisplatin alone. Such results indicate that LH weakens the anti‑tumor effect of cisplatin in vivo and that LH may contribute to the development of drug resistance to cisplatin in ovarian cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results